Pharmacogenetic aspects of the use of oral contraceptives and the risk of thrombosis
Authors:
- Ida MartinelliIMIda Martinelli
- Tullia BattaglioliTBTullia Battaglioli
- Pier Mannuccio MannucciPMPier Mannuccio Mannucci
- 1 October 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 13 (10) , 589-594
Abstract
Oral contraceptives are currently used by more than 100 million women in developed countries and are a highly efficacious method to prevent undesired pregnancies. However, oral contraceptives are associated with an increased risk of venous and arterial thrombosis, through changes in blood coagulation and fibrinolysis. In order to reduce such complications, the composition of oral contraceptives has changed over the past decades, both for the dose of oestrogen and the type of progestagen. However, the risk for venous thromboembolism remains, particularly for women who are carriers of inherited thrombophilia. In these women, prescription of oral contraceptives should be carried out on an individual basis. This review illustrates the risk of thrombosis, particularly venous thromboembolism, associated with the use of oral contraceptives, underlines the crucial role of the interaction of these drugs with other risk factors for the disease, and gives suggestions on the utility of thrombophilia screening before prescription.Keywords
This publication has 39 references indexed in Scilit:
- Risk Factors in Venous ThromboembolismThrombosis and Haemostasis, 2001
- Health consequences of combined oral contraceptivesBritish Medical Bulletin, 2000
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagenThe Lancet, 1995
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Oral Contraceptive Estrogen Dose and the Risk of Deep Venous Thromboembolic DiseaseAmerican Journal of Epidemiology, 1991
- Oral contraceptives and venous thromboembolism: findings in a large prospective study.BMJ, 1986
- THROMBOEMBOLISM AND ORAL CONTRACEPTIVERS: AN EPIDEMIOLOGIC CASE-CONTROL STUDY12American Journal of Epidemiology, 1969
- Investigation of Relation between Use of Oral Contraceptives and Thromboembolic Disease. A Further ReportBMJ, 1969
- PULMONARY EMBOLISMThe Lancet, 1961